Quarterly report · Q3

Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥618.0bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥214.7bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥703.3bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥523.5bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥178.8bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥93.5bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥37.5bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥94.5bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥28.6bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥92.1bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥114.5bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥93.0bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥27.8bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥71.7bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥21.7bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥71.7bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥21.7bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥1.54Tat 2022-12-31Cons.Assets IFRS
Total assets¥1.47Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.40Tat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥469.8bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥461.4bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥1.07Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥935.9bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥856.7bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥1.07Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.01Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥935.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥162.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥204.9bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥74.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥98.4bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥41.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥59.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥84.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥39.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥93.252022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥117.452021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥94.822021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥28.72021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥93.212022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥39.962022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥117.382021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥94.762021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥28.692021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio69.6%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥186m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥479m
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥113.4bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥358.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥83.6bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥145.5bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.6bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥617.8bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥109.1bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-12-31¥190m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.7bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2021-04-01 → 2021-12-31¥90.2bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2021-04-01 → 2021-12-31¥17.2bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2021-04-01 → 2021-12-31¥294.4bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2021-04-01 → 2021-12-31¥72.3bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2021-04-01 → 2021-12-31¥138.7bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2021-04-01 → 2021-12-31¥19.3bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥523.3bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥108.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 648
ItemContextValueUnit
Equity IFRSPrior1YearInstant_CapitalSurplusIFRSMember51921000000JPY
Equity IFRSPrior1YearInstant_TreasurySharesIFRSMember-6229000000JPY
Equity IFRSPrior1YearInstant_RetainedEarningsIFRSMember846978000000JPY
Equity IFRSPrior1YearInstant_OtherComponentsOfEquityIFRSMember80926000000JPY
Equity IFRSPrior1YearInstant_EquityAttributableToOwnersOfParentIFRSMember1012313000000JPY
Equity IFRSPrior1YearInstant1012313000000JPY
Profit loss IFRSCurrentYTDDuration_ShareCapitalIFRSMember-JPY
Profit loss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-JPY
Profit loss IFRSCurrentYTDDuration_TreasurySharesIFRSMember-JPY
Profit loss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember70180000000JPY
Profit loss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-JPY
Profit loss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember70180000000JPY
Profit loss IFRSCurrentYTDDuration70180000000JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember-JPY
Other comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-JPY
Other comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember-JPY
Other comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-JPY
Other comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember68964000000JPY
Other comprehensive income IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember68964000000JPY
Other comprehensive income IFRSCurrentYTDDuration68964000000JPY
Comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember-JPY
Comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-JPY
Comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember-JPY
Comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember70180000000JPY
Comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember68964000000JPY
Comprehensive income IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember139144000000JPY
Comprehensive income IFRSCurrentYTDDuration139144000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember-JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-56000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember-50002000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-50058000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration-50058000000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember-JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember17000000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember87000000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-105000000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember0JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration0JPY
Dividends ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember-JPY
Dividends ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-JPY
Dividends ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember-JPY
Dividends ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-27924000000JPY
Dividends ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-JPY
Dividends ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-27924000000JPY
Dividends ss IFRSCurrentYTDDuration-27924000000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass